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therapy. Persistence (remaining on therapy at 12 months after
therapy initiation), mean medication possession ratio (MPR)
over 12 months, and adherence (adherent to statin deﬁned as
MPR ≥ 0.8) were assessed. RESULTS: Among the 281,564
patients selected, 159,833 (56.8%) started on atorvastatin,
66,526 (23.6%) on simvastatin, 27,187 (9.7%) on pravastatin,
20,921 (7.4%) on ﬂuvastatin, and 7,097 (2.5%) on lovastatin.
The mean age was 61.3+/-13.2 years and 51% were male. The
persistence at 12 months, mean MPR over 12 months, and
adherence rate for all statins was 52.5%, 68.7%, 52.6%, respec-
tively. The persistence rate at 12 months for patients initiated on
atorvastatin, simvastatin, ﬂuvastatin, pravastatin, and lovastatin
was 54.1%, 53.7%, 49.7%, 44.8%, 41.0%, respectively (p <
0.0001 for all comparisons except for atorvastatin vs. simavas-
tatin). The mean MPR for patients initiated on atorvastatin, 
simvastatin, ﬂuvastatin, pravastatin, and lovastatin was 70.1%,
68.3%, 65.2%, 65.1%, and 62.2%, respectively (p < 0.0001 for
all comparisons except for ﬂuvastatin vs. pravastatin). Adher-
ence for patients initiated atorvastatin, simvastatin, pravastatin,
ﬂuvastatin, and lovastatin was 54.1%, 52.6%, 48.4%, 47.7%,
and 47.2% respectively (p < 0.0001 for all comparisons except
for pravastatin vs. ﬂuvastatin, pravastatin vs. lovastatin, and ﬂu-
vastatin vs. lovastatin). CONCLUSIONS: In general, patients
initiated on atorvastatin are most favorable in terms of persis-
tence, medication possession ratio, and adherence rates, followed
by simvastatin, ﬂuvastatin, pravastatin, and lovastatin patients.
While there are statistical signiﬁcant differences between the
agents, additional studies are needed to determine if this trans-
lates to clinical differences.
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OBJECTIVES: The preferred generic measure of health beneﬁt
in economic models is health-related utility. Utility provides a
single measure of health-preference and has interval properties.
A number of treatments are now available to treat obesity. The
purpose of this study was to characterise the relationship
between health utility and obesity as measured by body mass
index (BMI). METHODS: Data were extracted from the Health
Outcomes Data Repository (HODaR), which includes medical
histories (almost no exclusion criteria), biochemistry, health-
related utility (EQ5D), risk factors (including height and weight)
and demographic data on a large number of individuals. The
data used here (n = 18,223) were from hospital inpatients and
outpatients. Univariate analysis was conducted for speciﬁc sub-
groups and risk factors, as well as multivariate modelling.
RESULTS: The general pattern was non-linear (rotated J-shaped
curve). Naturally, there was wide variability but deﬁnite under-
lying structure to the relationship. People had highest utility
when BM I = 20kg·m-2. Below this, utility decreases rapidly.
There was a quadratic decrease in utility from BMI = 25kg·m-2
to BMI = 35kg·m-2 at a rate of 0.0133 utility units per unit BMI
between BMI = 29kg·m-2 to 30kg·m-2, increasing to 0.0325
between BMI = 34kg·m-2 and 35kg·m-2. This rate of deteriora-
tion was consistent for a range of sub-group analyses: age, sex,
employment status and by broad disease categories, the general
association remaining the same, only the intercept varying.
CONCLUSIONS: Health-related utility is a function of obesity.
These data characterise this relationship for the ﬁrst time, and
in a large group of subjects. The pattern of this association was
consistent in all subgroups investigated, and suggests that much
health beneﬁt can be achieved by reducing obesity in the general
population.
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OBJECTIVE: QOL is an important outcome in the evaluation
of weight loss interventions (e.g., drug therapy). The objective of
this study was to determine whether there are country-speciﬁc
differences in the perception of the impact of weight on quality
of life (QOL) or comfort with food. METHODS: The Impact of
Weight on Quality of Life Scale (IWQOL) was administered to
a sample of 2144 obese individuals [Mean body mass index
(BMI) =31.3, 63% > = 1 self-reported comorbidity, mean age =
41 years, 58% female] in Germany (n = 542), Italy (n = 503),
United Kingdom (UK) (n = 539), and United States (n = 560).
The IWQOL consists of 74 items forming 8 subscales: Health,
Social/Interpersonal, Sexual Life, Work, Self-Esteem, Mobility,
Activities of Daily Living, and Comfort with Food. For each
country, Pearson correlations were calculated between demo-
graphics and IWQOL scores. To control for demographic 
differences in country-speciﬁc samples, differences in IWQOL
scores were tested using analysis of covariance controlling for
BMI, total number of self-reported comorbidities, gender, 
and age. RESULTS: Correlations between demographics and
IWQOL subscales across countries followed a similar pattern,
but the correlation coefﬁcients calculated for Germany between
most IWQOL subscale scores and BMI or total comorbidities
were signiﬁcantly (p < 0.05) higher. Signiﬁcant (p < 0.05) country
differences were found for all IWQOL scales. Pairwise compar-
isons showed, for example, that, compared to the other three
countries, the UK sample had signiﬁcantly better Esteem and
Mobility scores; Germany had signiﬁcantly worse Social/Inter-
personal scores; and Italy had signiﬁcantly less comfort with
food (all p < 0.05). CONCLUSIONS: Differences in the per-
ceived impact of weight on QOL found in this study suggest the
need for more research investigating cultural differences in the
perception of obesity. Such differences may impact the inter-
pretation of patient-reported outcome scores obtained in 
international evaluations of obesity interventions.
CARDIOVASCULAR DISEASE (including Obesity)
CARDIOVASCULAR DISEASE (including Obesity)—
Health Policy Studies
PCV45
MECHANICAL AND ALLERGIC ADVERSE EVENTS RELATED TO
CENTRAL VASCULAR CATHETERS: EPIDEMIOLOGY IN THE
MEDICARE HOSPITALIZED SURGICAL POPULATION, 2002
Bright R1, Mermel L2, Richards C3,Yoder D4
1Food and Drug Administration, Rockville, MD, USA; 2Brown Medical
School & Rhode Island Hospital, Providence, RI, USA; 3Centers for
Disease Control and Prevention, Atlanta, GA, USA; 4Food and Drug
Administration, MD, USA
332 Abstracts
OBJECTIVE: To characterize MAAE related to CVC replace-
ment or placement among hospitalized Medicare surgical
patients. METHODS: The Centers for Medicare and Medicaid
Services sponsored identiﬁcation and abstraction of the records
for 40,620 hospitalizations of Medicare beneﬁciaries. Different
simple random sampling fractions were used for each of the 50
states. For patients undergoing surgery in the operating room,
details about each CVC (re-)placed during the hospitalization,
and related non-infectious adverse events, were noted.
RESULTS: Among 40,620 sample hospitalizations, 7044 CVCs
were (re-)placed during 4889 surgical hospitalizations (mean
length of stay 10.4d [95% CI: 9.7–11.2]); among these, there
were 159 MAAEs among 130 hospitalizations (mean length of
stay 20.1d [95% CI: 15.8–24.5]). The proportion of MAAEs per
catheter (re-)placement was 2.3% (95% CI: 1.9%–2.6%) and
the proportion of stays where a CVC was (re-)placed that had a
CVC-related MAAE was 2.7% (95% CI : 2.2%–3.2%). Among
patients who had length of stay up to 12 days and a CVC (re-
)placement, MAAE was associated with increased in-hospital
mortality (OR = 2.88, 95% CI: 1.53–5.43). Among those 
with CVCs (re-)placed, MAAE occurrence was unrelated to age.
The most common CVC (re-)placement sites were internal
jugular (40%) and subclavian veins (25%). The most common
speciﬁed CVC types were PICCs (19%) and pulmonary artery
catheters (16%). The most common hospital locations for (re-
)placement were operating rooms (35%) and critical care units
(17%). Most (72%) of the stays with CVC (re-)placement had
just 1; 20% had 2 CVC (re-)placements. The most common
MAAEs were misplacement (22%), thrombosis or embolism
(18%), coiling or kinking (10%), and pneumothorax (8%).
CONCLUSIONS: Among Medicare surgical inpatients, the 
rate of mechanical or allergic adverse events per catheter was
approximately 2%. Incomplete documentation was a barrier 
to studying speciﬁc types of CVCs in relation to MAAEs and
their risk factors.
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OBJECTIVE: The use of statins has been associated with risk
for myotoxicity. Myopathy, deﬁned as creatine kinase (CK) ele-
vation greater than 10 times the upper limit of normal (ULN),
occurs in 0.1–0.5% of statin users. This study describes elevated
CK levels in an HMO population on cholesterol lowering
therapy. METHODS: All subjects with a valid CK result during
January 1 to December 31, 2001 were studied. Pharmacy claims
data were linked to the laboratory results. A highly elevated
result was deﬁned as CK at least 10 ULN. RESULTS: A search
of laboratory data identiﬁed 13,624 subjects with valid CK
results. Most subjects had only one result (n = 10,301, 76%).
Seventy-six subjects (0.6%) had a highly elevated CK result.
Forty-one percent of all subjects (n = 5530) ﬁlled prescriptions
for statins only, 400 (3%) ﬁlled prescriptions for non-statin cho-
lesterol lowering therapy only, and 1473 (11%) ﬁlled prescrip-
tions for both types of cholesterol lowering medications. Highly
elevated CK results were found among 0.3% (n = 14) of statin
only subjects, 0.5% (n = 2) of non-statin therapy only subjects
and 0.6% (n = 9) of subjects with both medications. Of subjects
with no cholesterol therapy, 0.8% (n = 53 of 6621) had a highly
elevated CK result. CONCLUSIONS: We found a low rate of
highly elevated CK results among those for whom results were
available. The rate of highly elevated CK was higher among
those with non-statin cholesterol therapy or combination
therapy compared to those with statin therapy alone. Despite the
low occurrence of highly elevated results, we found that a large
percentage of those tested were statin users. The low incidence
of highly elevated CK among monitored statin users raises 
questions regarding the most effective strategy for identifying
patients at risk for myotoxicity.
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OBJECTIVE: To assess patient characteristics, risk factors and
antithrombotic treatment of atrial ﬁbrillation (AF), venous
thromboembolism (VTE), acute myocardial infarction (AMI),
and prophylaxis in orthopedic surgery (OS) in patients enrolled
in a national multicenter anticoagulation database. METHODS:
Data was retrospectively collected from hospital inpatient
records at 38 US hospitals. Patients treated from July 2000—
June 2003 with an ICD-9-CM or procedure code for AF, pul-
monary embolus (PE), DVT, pregnancy related PE or DVT, AMI,
total knee hip or knee replacement, and hip fracture surgery were
randomly selected. Patients under 18 years of age, and those
admitted from or discharged to another hospital were excluded.
Clinical characteristics and anticoagulation management accord-
ing to guidelines were analyzed. RESULTS: A total of 3778
patients were included (945 AF, 939 VTE, 966 AMI, and OS).
Mean age was 66.1 years with 53.3% male and 46.7% female.
Comorbidities included hypertension (59.9%), coronary artery
disease (35.5%), diabetes (21.5%), and malignancy (17.3%).
Surprisingly only 54.7% of AF patients with high stroke-risk
received warfarin and 20.6% received no treatment. Only 50.6%
of VTE patients had INR ≥ 2.0 two consecutive days prior to
discontinuing heparin. Only 60.5% of those without a thera-
peutic INR were discharged on bridge therapy. Length of hospi-
talization for bridged patients was signiﬁcantly less than those
discharged on chronic warfarin alone (4.0 vs. 8.1 days) (P <
0.001). Only 75.5% of AMI patients received aspirin on arrival
to the hospital, although 88% were discharged on aspirin and/or
warfarin. Only 85.6% of the OS population received prophy-
laxis with heparin or LMWH, the remaining received no anti-
coagulation. CONCLUSIONS: These results suggest that
evidence-based antithrombotic guidelines are not being consis-
tently followed. Further evaluation of antithrombotic practices
in those sites with the highest and lowest performance is 
warranted. It is hoped that this database will help demonstrate
gaps between guidelines and actual practice.
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OBJECTIVE: The basis of this study is to explore the different
contributing factors that affect excess weight gain among ado-
lescents. The different attributes that will be reviewed include:
the various genetic disorders, nutrition, food industry, physical
activity, sedentary activities, and the assortment of methods used
to measure to weight and body composition. METHODS: The
